Approaches to Binder Recovery Following Immunization Campaigns in Mouse Models
Harnessing the Potential of Human Lambda Light Chains in Antibody Discovery Campaigns
AET US 2023: Tackling Tough Targets in Antibody Discovery by Leveraging a Diverse Suite of In Vivo Discovery Platforms
Access the webinar recording Thanks for your interest in our recent AET US 2023: Tackling Tough Targets in Antibody Discovery by Leveraging a Diverse Suite of In Vivo Discovery Platforms webinar. Please fill out your contact information, and we will email you shortly with a link and passcode to access the recording. Our approach Initiating antibody […]
Fully Human Antibody Discovery Using Nanovials and Plasma Cells From ATX-GK™ Mice
Access the webinar recording Thanks for your interest in our recent Fully Human Antibody Discovery Using Nanovials and Plasma Cells From ATX-GK™ Mice webinar. Please fill out your contact information, and we will email you shortly with a link and passcode to access the recording. Our approach Plasma cells are an important source of antibodies and are important […]
Alloy Therapeutics Announces Scientific Advisory Board to Drive Roadmap of Biotherapeutic Discovery Platform Innovation
Alloy Therapeutics Announces Scientific Advisory Board to Drive Roadmap of Biotherapeutic Discovery Platform Innovation. BOSTON, Mass. – September 20, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced the formation of its scientific advisory board (SAB) that includes a group of renowned experts in fields spanning immunology, protein engineering, T cell receptor (TCR) modalities, and […]
Alloy Therapeutics to Empower Drug Discovery of Lundbeck’s Biologics for Brain Health
BOSTON, Mass. – May 2, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced it is collaborating with Lundbeck, a global pharmaceutical company specializing in brain diseases, in the discovery of novel biologics therapies. Through this agreement, Lundbeck will gain access to Alloy’s Antibody Discovery Services and its SeqImmune™ discovery module, which is a sequence-first workflow […]
Alloy Therapeutics Announces an Expansion of its Antibody Discovery Services in Conjunction with Two New Senior Vice Presidents
Alloy Antibody Discovery Services offers partners a modular campaign design that can meet their goals and budgets as they collaborate to discover the best antibodies with therapeutic potential. BOSTON, Mass. – April 26, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced the appointment of Kent Bondensgaard and John “Lippy” Lippincott as the latest members […]
Alloy Therapeutics and Normunity Sign Multi-Program Antibody Discovery Collaboration in Immuno-Oncology
— Partnership leverages Alloy’s high velocity antibody discovery offering to accelerate Normunity’s novel precision immuno-oncology pipeline — BOSTON, MA; November 17, 2022—Alloy Therapeutics, a biotechnology ecosystem company, announced an antibody discovery collaboration spanning multiple precision immuno-oncology programs for Normunity, a biotech company that recently announced its $65 million Series A financing. The collaboration will support the […]
Alloy Therapeutics Raises $42 Million Series D Financing to Accelerate Discovery Technology Development Across Biologic Modalities
— Following a successful expansion from antibodies into T-cell receptors and genetic medicines, Alloy will broaden its pre-competitive discovery technology and discovery services to enable innovative new therapeutic formats — BOSTON, MA; October 03, 2022—Alloy Therapeutics, a biotechnology ecosystem company, has closed $42 million in Series D financing led by its existing investors 8VC and Mubadala […]
ATX-Gx™ Biotech Licensee Discovering Novel Therapeutics
Alloy has more than 130 partners in the drug discovery ecosystem across academic, biotech, and large biopharma teams. Early in our history, we connected with Dren Bio, Inc., an emerging biopharmaceutical company headquartered in Northern California that specializes in the discovery of therapeutic antibodies engineered to selectively deplete pathologic cells and other disease-causing agents. Dren […]
